We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Anti-Aging Medical Group Corp., a specialty pharmaceutical company focused on developing, acquiring and commercializing innovative and scientifically proven products that offer both health maintenance and appearance enhancing benefits, announces the opening of the new Hong Kong office.
BioLineRx, Ltd., Israel's leading drug development company, today announced that it has signed an exclusive worldwide licensing agreement with Gevys Pharmaceuticals Ltd. for the development and commercialization of BL-3010, a novel approach for the treatment of acute and chronic pain.
Allergan, Inc. today announced that it has received the license from the European Commission to market Ganfort, Allergan's Lumigan/timolol combination product (bimatoprost/timolol ophthalmic solution) for the treatment of glaucoma, in the European Union.
Drugmaker Predix, based in Lexington, Mass., has completed enrollment for its first Phase III trial of PRX-00023, the company's treatment for patients with generalized anxiety disorder (GAD).
Final judicial approval has been given to an amendment to New Jersey-based Wyeth's national legal settlement related to fen-phen, clearing the way for the company to settle with the largest group of people who took the diet drugs fen-phen.
Genmab, headquartered in Denmark, has launched a late-stage pivotal study with HuMax-CD20 (ofatumumab) to treat patients with refractory B-cell chronic lymphocytic leukemia (CLL).
GlaxoSmithKline Plc hopes to grab the headlines at the world's top cancer meeting early next month with a barrage of data, including key trial results for a new breast cancer pill challenging blockbuster Herceptin.
Aida Pharmaceuticals, Inc., one of mainland China's leading pharmaceutical companies, today announced its financial results for the first quarter ended March 31, 2006.
Xethanol Corporation said its CoastalXethanol subsidiary has signed a letter of intent with Pfizer, Inc. to purchase Pfizer's pharmaceutical manufacturing complex located in Augusta, Georgia.